The results of another phase I (NCT01606241) clinical study, associated with patients with breast and ovarian cancer, have shown that five FRα-derived peptides are relatively safe; however, their therapeutic effectiveness needs further investigation [153]. This evidence concerns the gene FOLR1 and ovarian carcinoma.